The Comprehensive Genetic Test for Brugada Syndrome utilizes next-generation sequencing (NGS) to examine 7 genes associated with Brugada syndrome and cardiac sodium channelopathies. It is a targeted gene panel specifically designed to support accurate diagnosis, risk assessment, and prevention.
More Information
The Comprehensive Genetic Test for Brugada Syndrome is a targeted genetic test designed to evaluate hereditary causes of Brugada syndrome, a cardiac channelopathy affecting the electrical function of the heart. The comprehensive genetic test for Brugada syndrome includes the analysis of 7 genes, along with selected non-coding variants, enabling a focused assessment of genetic factors associated with this condition. It is particularly suitable for individuals with a clinical suspicion or diagnosis of Brugada syndrome. This disorder is characterized by specific electrocardiographic abnormalities and an increased risk of life-threatening arrhythmias in the absence of structural heart disease.
The comprehensive genetic test for Brugada syndrome includes key genes such as SCN5A, SCN1B, CACNA1C, CACNB2, and KCNE3, which are involved in cardiac ion channel function and the regulation of electrical activity. SCN5A encodes a cardiac sodium channel essential for depolarization, while CACNA1C and CACNB2 are involved in calcium channel function. These ion channels regulate the flow of ions across cardiac cell membranes, which is critical for normal cardiac conduction. Disruptions in these pathways lead to altered electrical signaling and increased susceptibility to arrhythmias. The comprehensive genetic test for Brugada syndrome is indicated in individuals presenting with clinical or electrocardiographic features suggestive of Brugada syndrome.
The clinical spectrum of Brugada syndrome includes syncope, ventricular arrhythmias, and sudden cardiac death, often occurring in individuals without structural heart abnormalities. Characteristic electrocardiographic findings include ST-segment elevation in the right precordial leads, although this may not be consistently present. Symptoms may occur at rest, during sleep, or be triggered by fever. Some individuals remain asymptomatic, while others may present with severe arrhythmic events. The condition shows significant variability in clinical expression and is more frequently observed in males and in individuals of Asian ancestry.
The purpose of the comprehensive genetic test for Brugada syndrome is to identify pathogenic variants associated with Brugada syndrome, supporting accurate diagnosis and differentiation from other arrhythmia disorders with overlapping features. Genetic findings contribute to improved understanding of the molecular mechanisms underlying cardiac channelopathies and support appropriate disease classification. The identification of specific genetic alterations assists in risk assessment, prognosis evaluation, and the development of individualized long-term monitoring strategies.
A higher genetic risk is confirmed when pathogenic mutations are found in genes associated with Brugada syndrome, including SCN5A, CACNA1C, and CACNB2. A lower risk may be inferred when no mutations are detected, though comprehensive clinical follow-up is still essential. The integration of genetic data with clinical findings and electrocardiographic evaluation is critical for precise diagnosis, prognosis, and long-term patient care.
The test is performed in a clinical laboratory accredited to ISO 15189 and certified by CLIA and CAP, ensuring the validity, accuracy and international recognition of the results.
